How to Read GLP-1 Research Without the Hype
Incretin drugs produced some of the largest weight-loss results in trial history. Understanding what those trials measured — and what they did not — is the difference between literacy and enthusiasm.
The incretin era has changed metabolic medicine faster than almost any therapeutic class in recent memory. It has also produced a volume of secondary commentary that frequently misstates what the underlying trials found.
Three questions clarify almost any GLP-1 headline: who was enrolled, what was measured, and what happened after the drug stopped.
Who was enrolled
The STEP and SURMOUNT programmes enrolled people meeting defined weight and comorbidity criteria, and provided structured lifestyle support in every arm — including placebo. That support is part of the result, not background noise.
Trial populations also skewed female and, in several trials, predominantly white. That does not invalidate the findings; it does mean effect estimates should be read as population averages under study conditions.
What was measured
Percentage change in body weight at a fixed week is a surrogate. It correlates with outcomes that matter, but it is not itself an outcome. The trials that measured hard endpoints — cardiovascular events, kidney progression — are a smaller and more important literature.
When a summary cites a weight percentage and a health claim in the same sentence, check whether the same trial produced both.
What happened after
Extension and withdrawal data consistently show substantial weight regain after discontinuation. This is a pharmacological finding about a chronic condition, not a failure of adherence.
It also reframes the practical question from how much weight a drug removes to what happens over years of use — a question the current evidence base is still answering.
Research references
- Randomised controlled trial2021
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
- Randomised controlled trial2022
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
This article is educational and is not medical advice. It does not recommend or provide individualised dosing. Speak with a qualified healthcare professional about your own health.